CA Patent

CA2912345C — Transplantation adjuvant in cell therapy using neural progenitor cells

Assigned to Sumitomo Pharma Co Ltd · Expires 2020-10-06 · 6y expired

What this patent protects

Provided is a transplantation adjuvant for neural progenitor cells, said transplantation adjuvant comprising valproic acid and/or zonisamide as active ingredient(s).

USPTO Abstract

Provided is a transplantation adjuvant for neural progenitor cells, said transplantation adjuvant comprising valproic acid and/or zonisamide as active ingredient(s).

Drugs covered by this patent

Patent Metadata

Patent number: CA2912345C
Jurisdiction: CA
Classification: —
Expires: 2020-10-06
Drug substance claim: No
Drug product claim: No
Assignee: Sumitomo Pharma Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.